Valbiotis SA (FR:ALVAL) has released an update.
Valbiotis, a French research lab focusing on dietary supplements for metabolic disorders, reported on their liquidity contract with Portzamparc, showing an inventory of 31,296 shares and 25,655.71 euros as of June 30, 2024. This reflects a dynamic trade period with 67,938 shares bought and 51,991 sold in the first half of 2024. The company emphasizes its commitment to innovation in health nutrition, aiming to reduce the risk of cardiovascular diseases.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.